Skip to main content

Table 2 Patients with reduced relative dose intensity (RDI) (percent of patients with reductions are presented)

From: The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study

  Planned RDI <85% of standard (%) Overall actual RDI <85% (%) RDI <85% for 1+ cycle (%) Planned RDI <90% of standard (%) Overall actual RDI <90% (%) RDI <90% for 1+ cycle (%)
All (n = 1,176)a 13.4 22.2 32.5 17.0 30.5 40.0
Age
 <50 years (n = 443) 12.4 16.0 26.0 15.3 23.5 33.2
 50–64 years (n = 537) 12.5 23.1 34.3 16.0 32.2 40.8
 ≥65 years (n = 196) 17.9 33.7 42.3 23.5 41.8 53.1
Menopausal statusa
 Pre-menopausal (n = 479) 10.4 14.4 23.4 12.9 21.7 30.3
 Post-menopausal (n = 690) 15.2 27.4 38.6 19.7 36.4 46.4
ECOG performance status
 0 (n = 917) 12.5 20.9 31.2 15.8 28.8 37.7
 1 (n = 235) 15.3 26.4 35.7 20.0 36.6 47.2
 2–4 (n = 24) 25.0 29.2 50.0 33.3 37.5 54.2
Prior chemotherapy
 No (n = 1,085) 13.1 21.9 32.4 16.7 30.1 39.9
 Yes (n = 91) 16.5 25.3 34.1 20.9 35.2 40.7
Baseline body surface area
 ≤2 m2 (n = 908) 10.7 19.9 30.3 13.9 28.2 38.0
 >2 m2 (n = 268) 22.4 29.9 39.9 27.6 38.4 46.6
Body mass indexa
 <30 kg/m2 (n = 750) 9.5 17.9 28.1 12.5 25.6 35.3
 30 to  <35 kg/m2 (n = 220) 16.8 30.0 38.6 20.0 36.8 45.0
 ≥35 kg/m2 (n = 203) 23.6 29.6 41.9 30.0 41.9 51.7
Hormone receptorsa
 ER+ or PR+ (n = 753) 13.9 22.0 32.9 18.1 30.3 41.2
 ER− and PR− (n = 378) 11.6 22.2 30.4 14.3 29.9 36.5
  1. ECOG Eastern Cooperative Group performance status, ER estrogen receptor, PR progesterone receptor, 1+ cycle at least one cycle.
  2. aFor some variables sample size is smaller due to missing data.